A Double-Blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Chinese Patients With Advanced Gastric Cancer

Trial Profile

A Double-Blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Chinese Patients With Advanced Gastric Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Cisplatin
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVATAR
  • Sponsors Roche
  • Most Recent Events

    • 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Oct 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov .
    • 14 Oct 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top